Business Context and Reporting Period
This Form 8-K Current Report was filed by Adial Pharmaceuticals, Inc. on August 21, 2023. The report addresses the Company's compliance status with The Nasdaq Stock Market LLC listing requirements following a period of non-compliance.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or debt). However, it confirms the following specific financial thresholds required for listing compliance:
- Stockholders' Equity: The Company confirmed it meets the minimum requirement of $2,500,000 under Nasdaq Listing Rule 5550(b)(1).
- Minimum Bid Price: The closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days (August 7, 2023, to August 18, 2023).
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq listing standards:
- Bid Price Compliance: The Nasdaq Staff determined the Company regained compliance with Listing Rule 5550(a)(2) regarding minimum bid price.
- Equity Compliance: On August 22, 2023, the Company received notice of compliance with Listing Rule 5550(b)(1) regarding stockholders' equity.
- Status: Both matters were declared closed by the Nasdaq Staff.
Outlook, Risks, and Management Commentary
On August 23, 2023, the Company issued a press release (Exhibit 99.1) announcing the receipt of these notices. The filing indicates that the immediate risk of delisting due to these specific criteria has been resolved. No forward-looking guidance, revenue projections, or new risk factors were disclosed in this specific report.
Investor Verification Checklist
- Verify the current trading price of common stock (ADIL) and warrants (ADILW) on the Nasdaq Capital Market.
- Review the attached press release (Exhibit 99.1) for any additional context on the Company's capital structure.
- Confirm the Company's most recent audited financial statements to validate the $2,500,000 stockholders' equity figure cited in the compliance notice.
- Monitor future filings for any recurrence of non-compliance notices regarding bid price or equity levels.